Xiangyang Xue

8PUBLICATIONS
13CO-AUTHORS
Predictive and prognostic markersMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Medical molecular engineering of nucleic acids and proteinsGenomics and transcriptomics
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 08, 2025
Multi‑omics identification of a novel signature for serous ovarian carcinoma in the context of 3P medicine and based on twelve programmed cell death patterns: a multi-cohort machine learning study.

Lele Ye, Chunhao Long, Binbing Xu

|Jul 11, 2024
Correction: NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation.

Yuanbo Hu, Chenbin Chen, Xinya Tong

|Mar 02, 2024
Elesclomol Loaded Copper Oxide Nanoplatform Triggers Cuproptosis to Enhance Antitumor Immunotherapy.

Xufeng Lu, Xiaodong Chen, Chengyin Lin

|Oct 22, 2021
mRNA modifications: clinical clarification and significance.

Kan Pan, Gangqiang Guo, Xiangyang Xue

|Sep 10, 2021
NSUN2 modified by SUMO-2/3 promotes gastric cancer progression and regulates mRNA m5C methylation.

Yuanbo Hu, Chenbin Chen, Xinya Tong

|Jul 18, 2020
TCONS_00483150 as a novel diagnostic biomarker of systemic lupus erythematosus.

Gangqiang Guo, Aqiong Chen, Lele Ye

Pageof 2

Frequent Collaborators

2 joint publications

Yuanbo Hu

2 joint publications

Xian Shen

2 joint publications

Mingdong Lu

2 joint publications

Gangqiang Guo